We engage in partnerships with innovators to push forward great science and continually seek new partners that are actively researching bold scientific ideas, capabilities and technologies that have the potential to bring innovative treatments to patients in need. Pfizer has several key areas of interest where we are looking to partner with others. Select an area below to see where we are focusing our partnering efforts.
Select an area below to see where we are focusing our partnering efforts.
Pfizer’s Hospital medicines reach patients at virtually every stage of life. The depth and breadth of our portfolio of trusted medicines and capabilities, and our presence in 160 countries, enables us to deliver value to patients throughout the world.
We are proud to provide access to our quality medicines to healthcare systems and patients in both developing and emerging markets. Pfizer’s Hospital medicines currently offers one of the industry’s largest and most diverse portfolios of anti-infectives and we’re a leader in sterile injectable manufacturing worldwide including the emerging markets.
Strategic Areas of Interest
Pfizer’s Hospital medicines reach patients at virtually every stage of life. The depth and breadth of our portfolio of trusted medicines and capabilities, and our presence in 160 countries, enables us to deliver value to patients throughout the world.
We are proud to provide access to our quality medicines to healthcare systems and patients in both developing and emerging markets. Pfizer’s Hospital medicines currently offers one of the industry’s largest and most diverse portfolios of anti-infectives and we’re a leader in sterile injectable manufacturing worldwide including the emerging markets.
Pfizer is a global leader in discovering and developing medicines for patients suffering from chronic immune diseases. Pfizer is committed to the discovery and development of novel therapeutics to help patients living with immune-inflammatory diseases. Pfizer Inflammation & Immunology is focused on discovering and developing the next generation of therapies for immune- mediated diseases. Pfizer is interested in entering into strategic relationships with innovative collaborators to develop novel and differentiated therapies for autoimmune diseases.
We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact three main areas:
Specific areas of interest include:
Not actively seeking partnering opportunities in:
Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for one in every two adult deaths worldwide. The rates of CVD-related morbidity, including heart-failure, peripheral arterial disease and nephropathy are increasing as more patients survive hearts attacks, and the population ages. In addition, Metabolic Diseases, specifically Type 2 diabetes (T2D) and obesity, are major health problems that have reached epidemic proportions worldwide. Globally T2D and obesity incidence have more than doubled in the past two decades. Importantly, CVD and T2D impose large economic burdens on the individual patient and on national healthcare systems and economies. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from CVD.
Pfizer is interested in partnering to develop therapeutics, expand our understanding of disease biology, and identify biomarkers that can help us impact:
Specific areas of interest include:
Not actively seeking partnering opportunities in:
Pfizer Oncology strives to advance the frontiers of cancer biology and to translate this knowledge into high-impact medicines for cancer patients. Our core areas of interest include: Tumor Cell Biology; Precision Medicine; Tumor Targeted Therapeutics; and Immuno-Oncology. In addition, our Integrative Biotechnology Group supports novel target identification and validation through functional genomics, proteomics, and other “omic” approaches.
We are interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:
Specific areas of interest include:
Immuno-Oncology
The clinical successes reported with cancer immunotherapy are reshaping the field of oncology. Pfizer is significantly advancing activity in this area by partnering to
develop cutting edge science beyond the current mainstream immune checkpoints. The IO programs at Pfizer uniquely leverage a combination of our scientific and clinical strength in immunobiology, as well as our historical expertise in developing first-in-class cancer therapies.
Pfizer’s efforts in IO include external collaborative alliances with leading academic medical centers and visionary biotech firms. Our IO efforts are driven primarily by the Cancer Immunology Discovery Unit (CID) within our La Jolla, CA-based laboratory site. Leveraging its strength in biotherapeutics, along with core expertise in immunobiology, CID has a strong record of converting validated targets into novel protein-based therapeutics and advancing molecular and cell-based IO treatments. We would like to partner in the IO space on pre-clinical and clinical-stage immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor-infiltrating immune cell populations.
We are interested in establishing alliances to develop and access:
Not actively seeking partnering opportunities in:
With the vision to be a leader in the development of therapeutic solutions for Rare Diseases, we have focused our business development strategy to align with the Category’s objective to identify and prioritize collaborations and partnerships to advance therapies for rare diseases where there remains high unmet need. Pfizer has adopted an innovative and collaborative approach to the development of new medicines for patients with rare diseases. We have a track record of creating innovative strategic partnerships with academic institutions, patient advocacy groups, and commercial enterprises to accelerate the development of novel therapeutics across a wide spectrum of rare diseases. Our expertise in small and large molecule therapeutics, and genetic therapies has resulted in a broad pipeline of potentially transformative medicines across four primary therapeutic areas, namely rare hematology, neurology, renal, cardiology and metabolic diseases. Therefore, we are seeking new business opportunities that span these disease indications and are not limited by molecule type.
Pfizer is interested in partnering to develop therapeutics, expanding our understanding of disease biology, and identifying biomarkers that can help us impact:
Specific areas of interest include:
Not actively seeking partnering opportunities in:
Vaccines are one of the greatest public health advancements of all time, resulting in the control, elimination, or near-elimination of numerous infectious diseases that were once pervasive and often fatal. Pfizer has a rich history in vaccine research and development. Over the years, we’ve played a pivotal role in eliminating or nearly eliminating deadly infectious diseases like smallpox and polio globally. We have designed novel vaccines based on new delivery systems and technologies that have resulted in vaccines to prevent bacterial infections, like those caused by S. pneumoniae and N. meningitidis.
Today, more people are benefiting from safe and efficacious vaccines to prevent infectious diseases than ever before, and vaccines provide essential health benefits at all ages, from maternal and infant populations to seniors. However, our work is not done given the many infectious diseases with high unmet medical need as well as the existence of a growing number of diseases which are potentially vaccine- preventable.
It is an exciting time in vaccine research and development, as scientific discoveries, technological advancements and regulatory paradigms are paving the way for novel vaccines. While Pfizer’s Vaccine Research and Development scientists continue to extend our leadership position in pneumococcal and meningococcal disease prevention, they are also working on vaccines against other major infectious diseases while striving to bring the benefits of vaccines into previously unexplored areas. We are at the forefront to usher in a new era of vaccine innovation, to prevent serious infectious diseases that span our life span, protecting infants through maternal immunization and infant immunization through to older adults.
The approval of the first mRNA-based COVID-19 vaccines was a scientific turning point, establishing mRNA as a versatile, flexible technology. The focus and drive Pfizer exhibited in developing our COVID-19 vaccine in partnership with BioNTech produced a wealth of scientific knowledge in just one year.
Pfizer’s next wave of mRNA scientific innovation is expanding in the infectious disease arena with development programs in influenza and shingles, and we are also exploring the application of mRNA technology in other areas, including in rare genetic diseases. Our intention is to evaluate opportunities where the scientific rationale for using mRNA technology along with Pfizer’s expertise in disease is strongest, and where the potential impact on patients could be the greatest.
Pfizer Vaccines is interested in partnering opportunities in Vaccines R&D:
Specific areas of interest in Vaccine Research include:
Broad platform technologies for application across multiple programs
We are interested in establishing alliances to develop and access novel:
Medicinal Chemistry Synthesis Technology
Medicinal Chemistry
Pharmacokinetics Dynamics and Metabolism (PDM)
Transformational technologies to design, construct, and optimize biotherapeutics
Bioconjugation technologies
Nucleic acid delivery technologies
Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
Structure-based and computational design of therapeutics including Artificial Intelligence and Machine Learning.
Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
Technologies and patient sample access for antibody discovery from human antibody responses
Targeted delivery technologies that address/overcome cell/tissue selectivity, cell membrane penetration, cross blood brain barrier
Integrated service providers to support early discovery activities for development of therapeutics
Broadly applicable platforms to enhance speed/quality of antibody generation
Novel biologics, combination therapies, and mRNA therapeutics that fit Pfizer strategies
Computational Product and Process Design (CPPD) – To complement and advance our experimentation and manufacturing processes with computational tools, including translating drug molecular structures to material properties in silico. Some of the areas of interest include in silico design & screening of synthetic pathways and structure-based stability prediction.
Materials Sciences and Particle Engineering – Development of molecular structure-based particle design and engineering tools that allow for the prediction and manipulation of crystal form/morphology, solid-state stability and material properties.
Portable, Continuous, Miniature and Modular Development and Manufacturing Equipment – Design and development of fit-for-purpose, small footprint, plug-and-play (modular) processing platforms, for drug product and API that allow the same equipment to be used for development and commercial manufacturing. Desired state is for processing modules to be capable of manufacturing multiple products at a wide range of scales and enable significant reduction in scale-up and technology transfer efforts.
Innovative Chemical Synthesis – Development of new platform syntheses that include sustainable/“green” chemical technologies and innovative chemical transformations. Partnerships in the areas of replacement of endangered metal catalysts and general methods for catalytic preparation of chiral amines are desired.
Drug Delivery Technologies – Advanced drug delivery technologies to enable differentiated therapies and the next generation of precision medicine. Specific areas of interest include:
Advanced Analytical Technologies – Innovative analytical platforms to enable real-time process understanding and/or control via on-line or at-line technology for Drug Product and API. Specific areas of interest include:
mRNA Vaccines
Process, analytical, formulation, delivery and biomanufacturing-enabling technologies
Gene therapy manufacturing technologies
Systems and Synthetic Biology
We are interested to ensure commercial and clinical differentiation of products by accessing leading drug delivery technologies.
Specific areas of interest include:
Pfizer is interested in partnering for the advancement of RNA therapeutics and the development of the next generation of RNA medicines
Novel target concepts and therapeutic strategies amenable to RNA based approaches (mRNA, circular RNA, gene editing, siRNA) and Technologies and Enabling Infrastructure, in the following areas of interest:
Pfizer's Drug Safety R&D scientists employ innovative sciences, next generation technologies and multi-dimensional expertise to quantitatively evaluate patient-centric safety of all targets, therapeutic candidates, and marketed products in Pfizer’s pipeline. Our scope spans the research, discovery, development, and commercialization phases to ensure development of an efficient risk management strategy using evidence-based forward and reverse translation of multi-modal datasets generated from non-clinical models and human studies.
Our focus areas include:
Translational safety sciences to predict safe human dose: Probabilistic early screening approaches coupled with mechanistic and translational investigations to understand, predict, detect, and mitigate toxicities in humans; for example:
Development, validation, and implementation of new drug development tools: Mechanistic de-risking using new tools that include AI/ML approaches, 2D and 3D human cell-based models, microphysiological and complex in vitro systems, and omics-based translational biomarkers; for example:
Support all therapeutic areas with an end-to-end non-clinical safety assessment approach: Execute safety packages for regulatory acceptances of IND/NDA/BLA submissions for all mono- and combination-therapy approaches (interpretation and translatability); for example:
Contribute to the biomedical ecosystem by mentoring; participating and leading of public-private partnerships, scientific and regulatory consortia, and conversations related to safety/regulatory guidance and policies
We are focused on Precision Medicine as an approach to discovering and developing potential treatments that can deliver superior outcomes for patients, by integrating clinical and molecular data to understand the biological basis of disease, the pharmacology of our drug candidates and the appropriate patient population to treat. Precision medicine efforts have the potential to lead to better matching of drug targets with selected patient populations that may experience clinical benefit.
We are interested in establishing collaborations to develop and access:
Patient cohorts
Systems Biology/Pharmacology
Biospecimen Analysis
Physiological Biomarkers
Induced pluripotent stem cell (iPSC) resources and technologies to generate iPSCs that may be used to enable Precision Medicine strategies
Biospecimen collection/stabilization technologies:
Remote Patient wearable technologies:
Advanced computational biology approaches/platforms:
Pharma R&D has been an emerging frontier for applying Artificial Intelligence (AI) techniques to design and develop medicines, with the goal of improving the speed and success of these steps. AI, as a blanket term for many advanced computational techniques, can have a major impact on speed and efficiency of drug discovery and development by leveraging data to identify novel targets, design new molecules, predict efficacy & safety of drugs, automate and generate documents to support development of potential pharmaceutical products, mine textual information to extract meaningful insights and more.
We are focusing our AI efforts in the areas where they couldhave the greatest impact to our pipeline, and are seeking partnerships to develop AI methodologies for the following applications:
Target & Indication Selection
Discovery of novel gene/disease linkages, new computational methods to confirm novel targets & biomarkers, and identify potential drug combinations by mining EMRs, Omics data, and publicly available textual information
Identify & Optimize Lead Matter
Design, screening, and optimization of novel, potential therapeutics using structure- and ligand- based generative approaches. Prediction of protein complexes and protein-ligand binding affinity.
Clinical Translation
Leveraging of data to obtain insights that may improve and accelerate clinical trials
Operational Efficiency
Optimization of end-to-end operations, with the goal of delivering therapies more rapidly and efficiently
Pfizer engages in a variety of partnership models that includes research collaborations, venture capital investments, academic alliances, early-stage seed funding, establishing incubators, licensing, and spinning out of companies.
Click below to connect with our team and learn more about our potential synergies, goals, needs and capabilities. There are patients who are waiting, and together, we might deliver on the promise of better health and longer lives.
We engage with academia and other public bodies in a range of partnerships.
Contacts:
Our biotech partnerships allow us to help you bring your drug or platform to market, with a focus on:
Contacts:
Our equity investments are active partnerships that seek to identify, support and grow good science from an early stage.
10.22.2024
09.03.2024
07.17.2024
05.23.2024
05.16.2024
02.12.2024
12.05.2023
12.04.2023
11.28.2023
11.16.2023
11.01.2023
10.15.2023